Clinical Trials
14 trialsNCT01228435 2017-12-04
IPI-504 in NSCLC Patients With ALK Translocations
Massachusetts General Hospital
Phase 2 Terminated
NCT00096109 2017-01-16
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00724425 2015-04-15
A Phase 1 Dose Escalation Study of IPI-493
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT01193491 2015-04-15
Dose Escalation of IPI-493 in Hematologic Malignancies
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00096005 2014-02-24
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00019708 2013-12-16
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00098488 2013-06-04
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00103272 2013-06-04
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00354185 2013-05-16
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00087386 2013-04-10
Tanespimycin in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00688766 2012-12-11
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
Infinity Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00817362 2012-12-11
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00627419 2012-12-10
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00319930 2010-03-08
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Biogen
Phase 1 Terminated